The short version of ACTH(4-10) fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | ~813.9 Da (free heptapeptide) | N-acetylated form is about 42 Da heavier |
| Residue count | 7 (heptapeptide) | Four residues from ACTH(4-10), three added |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility class | Freely soluble in water | Also dissolves in DMSO and polar organic solvents |
| Related parent fragment | ACTH(4-10) | Parent motif is Met-Glu-His-Phe |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
=== Quality and security === Open sourced models have fewer ways to prevent them from being used for malicious activities. Open-source AI may allow bioterrorism groups to remove fine-tuning and other safeguards of AI models. One proposed step towards reducing these kinds of harms could be to require models to have their risks evaluated and pass a certain standard before being released. A July 2024 report by the White House found it did not yet find sufficient evidence to restrict revealing model weights, though a number of experts in 2024 seemed more concerned about future advances than present-day capabilities. Executives that preferred proprietary models, in 2025, cited security concerns and performance as major factors why.
=== Average chemical characteristics === On average, healthy humans eliminate 128 g of fresh feces per person per day with a pH value of around 6.6 as indicated by a Fecal pH test. Fresh feces contains around 75% water and the remaining solid fraction is 84–93% organic solids along with some insoluble phosphate salts. These organic solids consist of: 25–54% bacterial biomass, 2–25% protein or nitrogenous matter, 25% carbohydrate or undigested plant matter, and 2–15% fat. Protein and fat come from the colon due to secretion, epithelial shedding, and gut bacterial action. These proportions vary considerably depending on many factors but mainly diet and body weight. The remaining solids are composed of insoluble calcium and iron phosphate salts, intestinal secretions, small amounts of dried epithelial cells, and mucus.
where ABCD+ is selected by MS1, dissociates into molecule AB and ion CD+. The ion is selected in the second mass spectrometry stage MS2 then undergoes further fragmentation to form ion D+ which is selected in the third mass spectrometry stage MS3 and detected. Multiple reaction monitoring (MRM) is the application of selected reaction monitoring to multiple product ions from one or more precursor ions, for example
==== Retail cooperatives ==== Another response to the success of the chain stores was the development of retail cooperatives. These organizations were founded by groups of individual food distributors who saw the benefits of using chain-style pricing. Retail cooperatives accounted for 7% to 8% of the food market in 1930, and an increase in their popularity with independent food distributors rose retail cooperative's market share to 13% by 1958.
During the 19th century, following the discovery of the first tombs and artifacts in Egypt, egyptology became popular in Europe, especially in Victorian England. European aristocrats would occasionally entertain themselves by purchasing mummies, having them unwrapped, and holding observation sessions. The pioneer of this kind of entertainment in Britain was Thomas Pettigrew known as "Mummy" Pettigrew due to his work. Such unrolling sessions destroyed hundreds of mummies, because the exposure to the air caused them to disintegrate. While mummies were used in medicine, some researchers have brought into question these other uses such as making paper and paint, fueling locomotives and fertilizing land. The use of mummies as fuel for locomotives was documented by Mark Twain, likely humorously, but the truth of the story remains debatable. During the American Civil War, mummy-wrapping linens were said to have been used to manufacture paper. Evidence for the reality of these claims is still equivocal. Researcher Ben Radford reports that, in her book The Mummy Congress, Heather Pringle writes: "No mummy expert has ever been able to authenticate the story ... Twain seems to be the only published source – and a rather suspect one at that". Pringle also writes that there is no evidence for the "mummy paper" either. Radford says that many journalists have not done a good job with their research, and while it is true that mummies were often not shown respect in the 1800s, there is no evidence for this rumor.
Sources: en.wikipedia.org
A PLC assembly consists of seven subunits, including the transporters associated with antigen processing (TAP1 and TAP2 – jointly referred to as TAP), the oxidoreductase ERp57, the MHC-I heterodimer, and the chaperones tapasin and calreticulin. TAP transports proteasomal degradation products from the cytosol into the lumen of the ER, where they are loaded onto MHC-I molecules. The peptide-MHC-I complexes then move via a secretory pathway to the cell surface, presenting their antigenic load to cytotoxic T-cells. In general, preliminary MHC-I heavy chains are chaperoned by the calnexin–calreticulin system in the ER. Together with β2-microglobulin (β2m), MHC-I heavy chains form assemblies of heterodimers that act as receptors for antigenic peptides. Empty MHC-I heterodimers are recruited by calreticulin and form short-lived macromolecular PLC where the chaperone tapasin further provides stabilization in the MHC-I molecules. Furthermore, ERp57 and tapasin form disulfide-linked conjugates, and tapasin is crucial for maintaining the structural stability of the PLC as well as facilitating optimal peptide loading. After final quality control, during which MHC-I heterodimers undergo peptide editing, stable peptide–MHC-I complexes are released to the cell surface for T-cell recognition. The PLC can serve a large variety of MHC-I allomorphs, thus playing a central role in the differentiation and priming of T lymphocytes, and in controlling viral infections and tumour development.
When naming a complex ion, the ligands are named before the metal ion. The ligands' names are given in alphabetical order. Numerical prefixes do not affect the order. Multiple occurring monodentate ligands receive a prefix according to the number of occurrences: di-, tri-, tetra-, penta-, or hexa-. Multiple occurring polydentate ligands (e.g., ethylenediamine, oxalate) receive bis-, tris-, tetrakis-, etc. Anions end in o. This replaces the final 'e' when the anion ends with '-ide', '-ate' or '-ite', e.g. chloride becomes chlorido and sulfate becomes sulfato. Formerly, '-ide' was changed to '-o' (e.g. chloro and cyano), but this rule has been modified in the 2005 IUPAC recommendations and the correct forms for these ligands are now chlorido and cyanido. Neutral ligands are given their usual name, with some exceptions: NH3 becomes ammine; H2O becomes aqua or aquo; CO becomes carbonyl; NO becomes nitrosyl. Write the name of the central atom/ion. If the complex is an anion, the central atom's name will end in -ate, and its Latin name will be used if available (except for mercury). The oxidation state of the central atom is to be specified (when it is one of several possible, or zero), and should be written as a Roman numeral (or 0) enclosed in parentheses. Name of the cation should be preceded by the name of anion. (if applicable, as in last example) Examples:
=== Deleterious === Deleterious outcomes represent the majority of nonsense mutations and are the most common outcome that is observed naturally. Deleterious nonsense mutations decrease the overall fitness and reproductive success of the organism. For example, a nonsense mutation occurring in a gene encoding a protein can cause structural or functional defects in the protein that disrupt cellular biology. Depending on the significance of the functions of this protein, this disruption could be detrimental to the fitness and survival of that organism.
In 1843, the Treaty of Nanking was signed by official representatives of both Britain and China. It allowed the opening of five major Chinese ports, granted extraterritoriality to foreigners and their activities in China, indemnification for the opium destroyed and completed the formal acquisition of the island of Hong Kong, which had been officially taken over as a trading and military base since 26 January 1841, though it had already been used years earlier as a transhipment point. Trade with China, especially in the illegal opium, grew, and so did the firm of Jardine, Matheson & Co., which was already known as the Princely Hong for being the largest British trading firm in East Asia. By 1841, Jardine had 19 intercontinental clipper ships, compared to close rival Dent and Company with 13. He also had hundreds of small ships, lorchas and small smuggling craft for coastal and upriver smuggling. In 1841, Jardine was elected to the House of Commons, a Whig Member of Parliament (MP) representing Ashburton in Devon. He was also a partner, along with Magniac, in the merchant banking firm of Magniac, Smith & Co., later renamed Magniac, Jardine & Co., the forerunner of the firm Matheson & Co. Despite his nominal retirement, Jardine was still very much active in business and politics and built a townhouse in 6 Upper Belgrave Street, then a new upscale residential district in London near Buckingham Palace. He had also bought a country estate, Lanrick Castle, in Perthshire, Scotland.
Sources: en.wikipedia.org
==== Mechanism of action ==== Propranolol is a non-selective beta receptor antagonist. This means that it does not have preference to β1 or β2 receptors. It competes with sympathomimetic neurotransmitters for binding to receptors, which inhibits sympathetic stimulation of the heart. Blockage of neurotransmitter binding to β1 receptors on cardiac myocytes inhibits activation of adenylate cyclase, which in turn inhibits cAMP synthesis leading to reduced Protein kinase A (PKA) activation. This results in less calcium influx to cardiac myocytes through voltage-gated L-type calcium channels, meaning there is a decreased sympathetic effect on cardiac cells, resulting in antihypertensive effects including reduced heart rate and lower arterial blood pressure. Blocking neurotransmitter activity at β2 receptors in vascular smooth muscle cells causes vasoconstriction, leading to hypertension.
== Further reading == Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, et al. (January 2020). "DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)". Plastic and Reconstructive Surgery. 145 (1): 45–58. doi:10.1097/PRS.0000000000006327. PMC 6940025. PMID 31609882. Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A". Drugs. 81 (18): 2091–2101. doi:10.1007/s40265-021-01631-w. PMC 8648634. PMID 34787840.
=== Measuring methods for contents of cannabinoids === Measuring methods for cannabinoids are based on the extraction of fluids from the hemp plant. Research and studies conducted at the University of Wuppertal (Germany) have shown that extracts contain much less of the initial contents of the hemp plant present in the juice. Besides, with extracts there is a risk of residues of solvents. There are no specific measuring methods for the quantities of cannabinoids in hemp juice accepted by all states. The EU is working on the development of a commonly accepted procedure. An alternative procedure used for the extraction of fluids first filters and centrifuges the hemp juice. The findings however showed no traces of cannabinoids because the characteristic contents of the hemp plant solely can be found in the unfiltered hemp juice.
Diabetes was one of the first diseases described, with an Egyptian manuscript from c. 1500 BCE mentioning "too great emptying of the urine". The Ebers papyrus includes a recommendation for a drink to take in such cases. The first described cases are believed to have been type 1 diabetes. The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Apollonius of Memphis. The disease was considered rare during the time of the Roman Empire, with Galen commenting he had seen only two cases during his career. This is possibly due to the diet and lifestyle of the people of that time, or because the clinical symptoms were only observed during the advanced stage of the disease. Galen named the disease "diarrhea of the urine" (diarrhea urinosa). Indian physicians around the sixth century CE identified the disease and classified it as madhumeha or "honey urine", noting the urine would attract ants. The earliest surviving work with a detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rd century CE). He described the symptoms and the course of the disease, which he attributed to moisture and coldness, reflecting his beliefs in the "Pneumatic School" of medicine. He hypothesized a correlation between diabetes and other diseases, and he discussed differential diagnosis from a snakebite, which also provoked excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.
However, the ability to develop primers and probes to more specifically target key microbial groups has been hindered by the lack of full-length 16S rRNA sequences, since sequences produced by the Illumina platform are of insufficient length (approximately 250 base pairs) for the design of primers and probes. In 2019, Goldsmith et al. demonstrated Sanger sequencing was capable of reproducing the biologically relevant diversity detected by deeper next-generation sequencing, while also producing longer sequences useful to the research community for probe and primer design (see diagram on right).
Sources: en.wikipedia.org
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.
Semax is a synthetic analog of the ACTH(4-10) fragment rather than a copy of the full hormone. Truncation plus the added tail removes the steroidogenic portion of ACTH. That distinction explains why it is studied for nervous-system effects instead of adrenal stimulation.
It is registered as a prescription product in Russia and has been used there clinically, chiefly by the intranasal route. No approval exists in the United States or the European Union. Availability elsewhere typically falls under research-chemical distribution, with varying purity documentation.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.